Sign In
Buy ABBV
$224.93
+7.86 (+3.62%)
At Close: Jun 04, 2026
AbbVie (ABBV) Rises As Market Takes a Dip: Key Facts
06:46pm, Monday, 03'rd Mar 2025
AbbVie (ABBV) closed the most recent trading day at $211.48, moving +1.17% from the previous trading session.
AbbVie Becomes Another Big Pharma To Enter Obesity Treatment Race
02:07pm, Monday, 03'rd Mar 2025
On Monday, AbbVie Inc ABBV and Gubra A/S announced a license agreement to develop GUB014295, a long-acting amylin analog for obesity. GUB014295 is currently in a Phase 1 clinical trial.
AbbVie Joins Obesity Treatment Market With Up to $2.2B Licensing Deal
02:01pm, Monday, 03'rd Mar 2025
AbbVie (ABBV) has agreed to license a weight-loss drug currently in development from Danish biotech firm Gubra for up to about $2.2 billion, signaling its entry in the obesity treatment market.
Final Trades: Taiwan Semi, Abbvie, Tradeweb Markets and the IYH
01:21pm, Monday, 03'rd Mar 2025
The Investment Committee give you their top stocks to watch for the second half.
ABBV Enters Obesity Bandwagon, Inks $2.2B Licensing Deal for Amylin Drug
10:01am, Monday, 03'rd Mar 2025
Per the terms of the deal, AbbVie will lead the development and commercialization of the obesity drug developed by Gubra.
AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity
01:45am, Monday, 03'rd Mar 2025
HØRSHOLM, DK / ACCESS Newswire / March 03, 2025 / Gubra (CPH:GUBRA) Partnership marks AbbVie's entrance into the obesity field Agreement will enable the incorporation of GUB014295, an amylin peptide
AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity
01:11am, Monday, 03'rd Mar 2025
Partnership marks AbbVie's entrance into the obesity field Agreement will enable the incorporation of GUB014295, an amylin peptide discovered and developed by Gubra, into AbbVie's global infrastructur
4 Sectors That Thrive When Inflation Runs Hot
07:45am, Friday, 28'th Feb 2025
On February 28, investors will get the January reading of the Personal Consumption Expenditure (PCE) index. Spoiler alert: it's expected to show inflation continues to run hot.
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Giant Cell Arteritis
02:00am, Friday, 28'th Feb 2025
The positive opinion is based on results from the pivotal Phase 3 SELECT-GCA trial that evaluated the efficacy and safety of upadacitinib in adults with giant cell arteritis (GCA)1 The primary endpo
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
05:47am, Thursday, 27'th Feb 2025
Imagine being able to buy a machine that would work day after day and year after year to make you money. Now imagine being able to buy several such machines.
2025 Dividend Kings - Off To A Strong Start
07:07pm, Wednesday, 26'th Feb 2025
The Dividend Kings are outperforming the S&P 500 in 2025, up 4% YTD versus 1.39% for SPY. Ten Dividend Kings have already achieved double-digit returns, led by National Fuel Gas (+22.08%) and Abbott L
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
10:05am, Wednesday, 26'th Feb 2025
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
AbbVie to Present at the TD Cowen's 45th Annual Health Care Conference
08:00am, Wednesday, 26'th Feb 2025
NORTH CHICAGO, Ill. , Feb. 26, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the TD Cowen's 45th Annual Health Care Conference on Wednesday, March 5, 2025.
Don't Get Left Behind - The Great Rotation Into Dividend Stocks Is Here
07:30am, Monday, 24'th Feb 2025
Despite significant market events, industrial and tech stocks have had similar returns since 2020, indicating a potential long-term rotation favoring value stocks. Higher inflation and interest rates
Why AbbVie Remains A Strong Buy For Long-Term Investors
11:52am, Sunday, 23'rd Feb 2025
Why AbbVie Remains A Strong Buy For Long-Term Investors
